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Abstract  
BACKGROUND: Myeloperoxidase (MPO) is an enzyme involved in the pathogenesis of several diseases.  
AIM: The current study aimed to investigate serum MPO levels in obese Egyptian women and assess its relation 
with insulin resistance (IR) and other biochemical risk parameters.  
METHODS: The study included 80 obese women and 50 age-and-sex-matched healthy controls. Insulin 
resistance (IR) was evaluated by the Homeostasis Model Assessment-Insulin Resistance (HOMA-IR).  Serum 
MPO, fasting glucose, insulin and blood lipids and anthropometry were measured. Obese cases were divided into 
three groups based on MPO tertiles. ROC analysis was performed to obtain the optimal cut-off values of MPO to 
predicate IR in obese women.  
RESULTS: The mean serum MPO was significantly higher in obese cases than controls. Cases in the highest 
MPO tertile had higher HOMA-IR, blood lipids and pressure levels compared with those in the lower tertile. The 
cutoff point of MPO was > 87.8 (ng/mL) and area under curves was 0.82 (p < 0.01) for diagnosis of IR. MPO 
levels were higher in obese Egyptian women than healthy controls.  
CONCLUSION: Elevation of MPO was associated with abnormal metabolic parameters. MPO might be used as 
an earlier biomarker for IR and metabolic disturbance in obese women. 
 
 
 
 
 
 
 
 
 
Introduction 
 
MPO is a heme peroxidase that is highly 
expressed in leukocytes and considered as a principal 
enzyme in the innate immune response. It is 
substantially stored in cytoplasmic granules and might 
be discharged into the extracellular compartment 
following phagocyte activation [1]. As MPO can 
commence lipid peroxidation process, it acts as an 
earlier marker of oxidative damage [2]. In this regard, 
lots of evidence indicate the association between the 
oxidative stress and metabolic syndrome (MS) 
parameters [3] [4], where oxidative stress affects the 
pathophysiology of MS and its components [5]. 
Although MPO plays an important role in the innate 
immune system, it has a very deleterious effect on a 
large number of inflammatory-mediated diseases. It 
has been found in cases with an acute coronary 
syndrome that the serum level of MPO is highly 
correlated with elevated risk of subsequent 
cardiovascular diseases.  
Central obesity, dyslipidemia, insulin 
resistance, and hypertension constitute the main 
components of the metabolic syndrome and 
metabolically linked to cardiovascular risk factors [6]. 
Levels of antioxidants in metabolic syndrome cases 
varied in different races [7]. Plasma levels of MPO are 
found to be high in patients with stable coronary artery 
disease. Furthermore, it has been demonstrated that 
MPO is a powerful prognosticator of the undesirable 
clinical outcomes in cases with chronic heart failure, 
acute coronary syndrome, and of future coronary 
artery disease in a healthy population. Moreover, the 
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main risk factor for cardiovascular diseases and 
mortality, type 2 diabetes, is positively correlated with 
MPO levels [8]. It seems that the MPO plays a role as 
a mediator in the vascular inflammation and in the 
production of oxidant species that are important in the 
pathophysiology of the inflammatory diseases. 
Therefore, this study aimed to evaluate the 
association between serum levels of MPO with 
metabolic and biochemical parameters in obese 
women. 
 
 
Methods 
 
The study sample included 80 obese women 
and 50 age-and-sex-matched healthy controls. Obese 
cases were divided into three groups according to 
MPO tertiles. This research has been approved by the 
Ethical Committee of National Research Centre, 
Egypt (number = 16361), by the World Medical 
Association’s Declaration of Helsinki.  
All patients and controls were subjected to full 
medical history and clinical examination. All 
anthropometric measurements were taken 3 times on 
the left side of the body, and the mean of the 3 values 
was used. Body weight was measured to the nearest 
0.1 kg and height was measured to the nearest 0.1 
cm. Height was measured with the patients standing 
with their backs leaning against a stadiometer scale. 
BMI was calculated as weight in kilograms divided by 
height in meters squared (kg/m
2
). Waist circumference 
(WC) and hip circumference (HC) were measured in 
cm using a plastic, non-stretchable tailor’s tape. WC 
was measured with light clothing at a level midway 
between the lower rib margin and the iliac crest 
standing and breathing normally. HC was measured 
at the level at the widest circumference over the 
buttocks (at the greater trochanter). Subsequently, the 
waist-hip ratio (WHR) was calculated as WC divided 
by HC. Skin-fold thickness was measured to the 
nearest mm, except for low values (usually 5 mm or 
less) where it was taken to the nearest 0.5 mm. These 
readings were done at the biceps, triceps, 
subscapular, supra-iliac and abdominal areas using 
Holtain calliper. The biceps skin-fold thickness was 
measured at the level of the mid-point between the 
acromion (lateral edge of the acromion process) and 
the radius (proximal and lateral border of the radius 
bone) on the mid-line of the anterior surface of the 
arm. Triceps skin-fold thickness was measured 
vertically at the midway between acromion and 
olecranon processes on the posterior surface of the 
arm. The subscapular skin-fold was measured below 
the lower angle of the left scapula at a diagonal in the 
natural cleavage of the skin. The position of the 
suprailiac skinfold was the diagonal fold just above the 
iliac crest even with the anterior axillary line. 
Abdominal skin-fold was at 5 cm adjacent to the 
umbilicus to the right side. Subsequently, the sum of 
skinfolds was calculated. Anthropometric 
measurements were obtained according to 
standardised equipment and following the 
recommendations of the International Biological 
Program [9]. Body fat % was assessed by Tanita 
Body Composition Analyzer (SC -330). 
Presence of IR was defined by HOMA-IR > 
2.47 [10]. 
Systolic and diastolic blood pressures (SBP 
and DBP) have been measured twice in the right arm 
in a sitting position after a 10-min rest period, and the 
average of the two measurements was used for 
analysis. Blood pressure was measured according to 
a standardised operating procedure using a calibrated 
sphygmomanometer and brachial inflation cuff (HEM -
7200 M3, Omron Healthcare, Kyoto, Japan).  
Venous blood samples were collected by 
direct  venipuncture after an overnight fast (minimum 
12 h). Fasting plasma glucose and serum lipids (total 
cholesterol, high-density lipoprotein cholesterol (HDL-
C) triglycerides (TG) were measured by enzymatic 
colourimetric methods using a Hitachi autoanalyser 
704 (Roche Diagnostics. Switzerland). Low-density 
lipoprotein cholesterol (LDL-C) was calculated 
according to certain equation (LDL – C = Total 
cholesterol-Triglycerides/5 + HDL-C). Serum insulin 
concentration was  analysed by chemiluminescent 
immunoassay (Immulite2000, Siemens, Germany. 
Insulin resistance was determined by the 
Homeostasis Model Insulin Resistance (HOMA-IR) is 
calculated as the product of the fasting plasma insulin 
level (IU/mL) and the fasting plasma glucose level 
(mmol/L), divided by 22.5 [11]. Clinical history and 
physical examination were performed for each 
subject.  
Serum myeloperoxidase (MPO) was 
estimated using Quantikine ELIZA kit of R&D systems 
catalogue number DMYE00B for the quantitative 
determination of human MPO concentration in serum 
according to the manufacturer’s instructions. 
All statistical analyses were performed using 
SPSS16.0 for Windows (SPSS Inc). The Kolmogorov-
Smirnov test of normality was used to verify whether 
the distribution of variables followed a Gaussian 
pattern. Normally distributed data in groups were 
expressed as means ± SDs. A receiver operating 
characteristic (ROC) curve analysis was performed to 
obtain the optimal cutoff values of MPO to diagnosis 
IR. The optimal cutoff values were obtained both from 
the point on the ROC curve. The area under the curve 
(AUC) and the 95% confidence interval (CI) were 
used for diagnostic validity. The Youden index, 
calculated as (sensitivity + specificity-1) was 
estimated to determine optimal cut-off. 
Differences in clinical and biochemical 
characteristics between groups were tested using 
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one-way analysis of variance (ANOVA) and post hoc 
tests for differences between groups. 
 
 
Results 
 
Table 1 shows the clinical and biochemical 
characteristics of obese cases and controls. Mean 
age of obese women participated in the study was 
31.5 ± 4.8 years and was 32.7 ± 4.7 in controls. 
Obese women showed significantly higher values of 
BMI, MPO, waist circumference, SBP, DBP, FBG, 
total cholesterol, TG, LDL-C and lower HDL-C than 
controls.  
Table 1: Clinical and biochemical characteristics of obese 
cases and controls  
Characteristics Obese Controls 
Age (years) 31.5 ± 4.8 32.7 ± 4.7 
BMI (kg/m
2
) 32.21 ± 5.4* 22.24 ± 4.2 
WC (cm) 96.2 ± 6.12* 81.6 ± 4.3 
WHR 0.82 ± 0.8 0.79 ± 0.6 
Sum SF 149. 9 ± 23. 9 143.9 ± 21.9 
Body fat% 29.9 ± 9.9 27.5 ± 8.4 
SBP (mmHg) 135.55 ± 9.8* 100. 3 ± 9.4 
DBP (mmHg) 88.8 ± 6.9* 65.24 ± 8.8 
HOMA-IR 6.8 ± 1.2* 2.2 ± 1.2 
FBG (mg/dL) 111.4 ± 24.7* 81. 0 ± 21.1 
TC (mg/dL) 189.9 ± 36.2* 118.9 ± 22.2 
TG (mg/dL) 146.8 (120-148.8) * 47.55 ± 10.45 
HDL-C (mg/dL) 35.6 ± 4.9* 47.77 ± 10.8 
LDL-C (mg/dL) 163 (88-162)* 165 (88-164)* 
MPO ( ng/mL ) 86 (66 – 92)** 22 ± 12 (20–30) 
BMI: body mass index; WC: waist circumference; WHR: waist to hip ratio; Sum SF: sum of 
skin folds; SBP: systolic blood pressure; DBP: diastolic blood pressure; HOMA-IR: 
homeostasis model assessment-insulin resistance; FBG: fasting glucose; TC: total 
cholesterol; TG: triglycerides; HDL -C: high density lipoprotein cholesterol; LDL-C: low 
density lipoprotein cholesterol; MPO: myeloperoxidase; *p < 0.05, ** p < 0.001. 
 
 
 
Biochemical and metabolic characteristics in 
obese women according to the different levels of MPO 
tertiles are summarised in Table 2. Compared with 
participants in the first tertile of MPO, those in the third 
tertile had higher levels of HOMA-IR, total cholesterol, 
TG, LDL-C, BP and lower levels of HDL-C. Fig 1 
shows ROC curves for MPO to identify IR in obese 
women, the cutoff points for MPO was > 87.8 (ng/mL) 
and area under curves was 0.82 (sensitivity 93.7%, 
specificity 71.4%) as a most sensitive/specific cut off.  
 
 
Figure 1: the Receiver-operating characteristic curve of sensitivity 
plotted against1-specificity of serum MPO to identify IR among 
obese women 
Table 2: Biochemical and metabolic characteristics in obese 
women according to the Myeloperoxidase (MPO) tertiles 
Characteristic I 
Lower tertile 
≤ 61.7 
II 
Intermediate tertile 
61.8-82.6 
III 
Higher tertile 
> 82.7 
Age (years) 31.2±4.1 33.5±3.5 31.1 ±4.8 
BMI(kg/m2) 31.8 ± 5.4 33.4 ± 6.6 34.9 ± 6.23 
WC (cm) 86.0 ± 10.9 87.9 ± 11.1 96.9 ± 10.9* 
WHR 0.7 ± .8 0.8 ± .7 0.9 ± .9 
Sum SF 131.6 ±10.5 134.2 ± 11.0 138.4 ± 14.9 
Body fat% 29.9 ± 9.8 32.6 ± 10.9 33.5 ± 12.8 
SBP (mmHg) 111.1±10.5 125.4 ± 9.4 151.3 ± 11.4* 
DBP (mmHg) 71.5 ± 8.6 76.3±6.8 89.9±8.5* 
HOMA-IR 3.5 ± 1.1 3.7 ± .7 5.6 ± 1.2* 
FBG (mg/dL) 83.1 ± 20.8 86.3 ± 25.7 121. 8 ± 22.9* 
TC (mg/dL) 136.7 ± 20.7 149.9 ± 21.9 193 ± 23.5* 
TG (mg/dL) 139.9 ± 20.2 149.8 ± 22.5 195.8 ± 21.5* 
HDL-C (mg/dL) 46.4 ± 10.5 41. 6 ± 11.4 35.4±12.2* 
LDL-C (mg/dL) 124.7 ± 21.3 129.3 ± 20.9 156.6 ± 21.9* 
MPO (µg/L) 54.1 (33.4-57.9) 69 (60.7-66.9) 91.3 (83.4- 96.9) * 
BMI: body mass index; WC: waist circumference; WHR: waist to hip ratio; Sum SF: sum of 
skin folds; SBP: systolic blood pressure; DBP: diastolic blood pressure; HOMA-IR: 
homeostasis model assessment-insulin resistance; FBG: fasting glucose; TC: total 
cholesterol; TG: triglycerides; HDL -C: high-density lipoprotein cholesterol; LDL-C: low-
density lipoprotein cholesterol; MPO: myeloperoxidase; Data are mean ± SD, median 
(intertertile range); Tertile I vs Tertile III *p < 0.05. 
 
 
Discussion 
 
This study showed that MPO is positively 
associated with IR in the obese women. As it is linked 
to obesity, IR is kept rising and consequently Type 2 
Diabetes affects a large number of young individuals 
[8]. It has been demonstrated that elevated 
concentrations of glucose and free fatty acids lead to 
oxidative stress and start IR in genetically 
predisposed individuals with diabetes [12]. Previous 
studies have found that MPO might be used as a 
predictor of both early [13] [14] and late unfavourable 
cardiac events in cases suffered from chest pain and 
other clinical features of the acute coronary syndrome. 
MPO plays an important role in the oxidation of HDL 
in vivo [14] which result in functional inactivation. The 
subsequent decrease in plasma HDL causes a 
reduction in the reverse cholesterol transport which 
stimulates atherosclerosis [15]. Moreover, HDL is a 
very important anti-inflammatory, antioxidant, and 
antithrombotic factor. In patients with metabolic 
syndrome, the activated leukocytes might be 
responsible for the increased activity of MPO. 
Furthermore, insulin resistance causes higher 
concentrations of proinflammatory mediators [16]. 
Also, the inflammatory cytokines are produced by 
adipocytes, especially in obese individuals, to 
compromise the insulin signalling [17]. In MS patients, 
both insulin resistance and central obesity are 
demonstrated, however, the association between the 
augmented MPO expression and chronic inflammation 
is also evident [18]. The connection between 
proinflammatory regulators and pathogenesis of the 
MS has been previously demonstrated, where the 
impairment in the inflammatory response could be 
noticed during the disease [19]. MPO acts as a 
physiological mechanism that connects the matrix 
proteins degradation by metalloproteinases.  
Our results found a higher concentration of 
MPO in obese group than controls. Also, we found 
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that cases in the higher tertile of MPO had higher 
levels of HOMA-IR, total cholesterol, TG, LDL-C, SBP, 
DBP and lower levels of HDL cholesterol than those in 
the lower tertile. The present analysis showed that the 
cutoff point of MPO was > 87.8 (ng/mL) for diagnosis 
of IR in obese Egyptian women (p < 0.01). In 
agreement with our findings, it has been previously 
reported that MPO is associated with IR [20]. It is 
evident that MPO is an effective mediator of 
endothelial dysfunction where a strong connection has 
been observed between serum MPO levels and 
endothelial dysfunction in overweight subjects [21]. 
Obesity is the principal cause for low HDL, and in 
order to enhance the HDL level, an optimizing healthy 
lifestyle is required including moderate weight loss 
along with exercise and smoking cessation. High 
oxidative stress and systemic inflammation are 
correlated with increased plasma triglyceride-rich 
lipoproteins and oxidized lipoprotein (a) phospholipids 
which lead to cardiovascular risks [22] [23]. Losing of 
the anti-oxidative, anti-inflammatory and athero-
protective properties of HDL and its apolipoproteins 
could even increase those biochemical disturbances. 
Metabolic disorders such as insulin resistance, 
oxidative stress, inflammation, and hyperlipidemia 
represent connected disturbances in women with 
metabolic syndrome [24]. Obesity has certain 
anthropometric, biochemical and physiological 
anomalies that lead to IR and cardiovascular disease 
(CVD). Therefore, numerous studies have indicated 
the associations between obesity, inflammation, CVD 
and IR in both adults and children [25]. MPO activity 
was used as an adjuvant marker for the inflammatory 
and oxidative status in obese women [26] [27] [28]. 
Also, there is increasing evidence that MPO 
contributes to cardiovascular disease. It has been 
reported that the presence of obesity in childhood 
stage in association with the risk factors hurt the 
vascular health status in adulthood [29]. Furthermore, 
in apparently healthy adults, augmented serum MPO 
levels were found to be associated with higher CVD 
risk [30]. 
In conclusion, MPO might be used as an 
earlier biomarker for IR in obese women and might be 
useful in determining patients who are at high risk for 
a biochemical disturbance. 
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